(ENSG) The Ensign - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US29358P1012
Stock:
Total Rating 67
Risk 87
Buy Signal -0.10
| Risk 5d forecast | |
|---|---|
| Volatility | 24.0% |
| Relative Tail Risk | -8.81% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.77 |
| Alpha | 61.50 |
| Character TTM | |
|---|---|
| Beta | 0.236 |
| Beta Downside | 0.336 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.49% |
| CAGR/Max DD | 1.45 |
EPS (Earnings per Share)
Revenue
Description: ENSG The Ensign
The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The Skilled Services segment provides short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly; specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management; and standard services, such as room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. The Standard Bearer segment leases post-acute care properties to healthcare operators. In addition, the company operates senior living units; and provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. The company operates healthcare facilities in Alabama, Alaska, Arizona, Colorado, Idaho, Iowa, Kansas, Oregon, Nebraska, Nevada, South Carolina, Tennessee, Texas, Utah, Washington, and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 344.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.74 > 1.0 |
| NWC/Revenue: 7.47% < 20% (prev 9.72%; Δ -2.25% < -1%) |
| CFO/TA 0.10 > 3% & CFO 564.3m > Net Income 344.0m |
| Net Debt (3.65b) to EBITDA (567.9m): 6.43 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.3m) vs 12m ago 1.21% < -2% |
| Gross Margin: 13.74% > 18% (prev 0.16%; Δ 1359 % > 0.5%) |
| Asset Turnover: 99.84% > 50% (prev 91.24%; Δ 8.59% > 0%) |
| Interest Coverage Ratio: 58.04 > 6 (EBITDA TTM 567.9m / Interest Expense TTM 7.99m) |
Altman Z'' 2.69
| A: 0.07 (Total Current Assets 1.27b - Total Current Liabilities 894.3m) / Total Assets 5.46b |
| B: 0.32 (Retained Earnings 1.76b / Total Assets 5.46b) |
| C: 0.09 (EBIT TTM 463.6m / Avg Total Assets 5.07b) |
| D: 0.54 (Book Value of Equity 1.76b / Total Liabilities 3.23b) |
| Altman-Z'' Score: 2.69 = A |
Beneish M -2.89
| DSRI: 0.94 (Receivables 637.0m/569.9m, Revenue 5.06b/4.26b) |
| GMI: 1.14 (GM 13.74% / 15.67%) |
| AQI: 0.94 (AQ_t 0.07 / AQ_t-1 0.08) |
| SGI: 1.19 (Revenue 5.06b / 4.26b) |
| TATA: -0.04 (NI 344.0m - CFO 564.3m) / TA 5.46b) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of ENSG shares?
As of February 25, 2026, the stock is trading at USD 212.39 with a total of 406,255 shares traded.
Over the past week, the price has changed by -0.04%, over one month by +19.22%, over three months by +15.11% and over the past year by +64.80%.
Over the past week, the price has changed by -0.04%, over one month by +19.22%, over three months by +15.11% and over the past year by +64.80%.
Is ENSG a buy, sell or hold?
The Ensign has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy ENSG.
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ENSG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 220.4 | 3.8% |
| Analysts Target Price | 220.4 | 3.8% |
ENSG Fundamental Data Overview February 22, 2026
P/E Trailing = 36.1304
P/E Forward = 23.5849
P/S = 2.4202
P/B = 5.3326
P/EG = 1.5727
Revenue TTM = 5.06b USD
EBIT TTM = 463.6m USD
EBITDA TTM = 567.9m USD
Long Term Debt = 137.5m USD (from longTermDebt, last quarter)
Short Term Debt = 119.0m USD (from shortTermDebt, last quarter)
Debt = 4.15b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.65b USD (from netDebt column, last quarter)
Enterprise Value = 15.82b USD (12.24b + Debt 4.15b - CCE 572.4m)
Interest Coverage Ratio = 58.04 (Ebit TTM 463.6m / Interest Expense TTM 7.99m)
EV/FCF = 42.68x (Enterprise Value 15.82b / FCF TTM 370.7m)
FCF Yield = 2.34% (FCF TTM 370.7m / Enterprise Value 15.82b)
FCF Margin = 7.33% (FCF TTM 370.7m / Revenue TTM 5.06b)
Net Margin = 6.80% (Net Income TTM 344.0m / Revenue TTM 5.06b)
Gross Margin = 13.74% ((Revenue TTM 5.06b - Cost of Revenue TTM 4.36b) / Revenue TTM)
Gross Margin QoQ = 8.67% (prev 14.67%)
Tobins Q-Ratio = 2.90 (Enterprise Value 15.82b / Total Assets 5.46b)
Interest Expense / Debt = 0.05% (Interest Expense 1.96m / Debt 4.15b)
Taxrate = 26.56% (34.5m / 130.1m)
NOPAT = 340.5m (EBIT 463.6m * (1 - 26.56%))
Current Ratio = 1.42 (Total Current Assets 1.27b / Total Current Liabilities 894.3m)
Debt / Equity = 1.86 (Debt 4.15b / totalStockholderEquity, last quarter 2.23b)
Debt / EBITDA = 6.43 (Net Debt 3.65b / EBITDA 567.9m)
Debt / FCF = 9.85 (Net Debt 3.65b / FCF TTM 370.7m)
Total Stockholder Equity = 2.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.79% (Net Income 344.0m / Total Assets 5.46b)
RoE = 16.58% (Net Income TTM 344.0m / Total Stockholder Equity 2.07b)
RoCE = 20.96% (EBIT 463.6m / Capital Employed (Equity 2.07b + L.T.Debt 137.5m))
RoIC = 15.36% (NOPAT 340.5m / Invested Capital 2.22b)
WACC = 5.07% (E(12.24b)/V(16.40b) * Re(6.78%) + D(4.15b)/V(16.40b) * Rd(0.05%) * (1-Tc(0.27)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.50%
[DCF] Terminal Value 86.66% ; FCFF base≈298.0m ; Y1≈308.0m ; Y5≈348.3m
[DCF] Fair Price = 115.3 (EV 10.35b - Net Debt 3.65b = Equity 6.70b / Shares 58.1m; r=5.90% [WACC]; 5y FCF grow 3.44% → 2.90% )
EPS Correlation: 98.15 | EPS CAGR: 17.63% | SUE: 1.39 | # QB: 1
Revenue Correlation: 99.49 | Revenue CAGR: 18.79% | SUE: -1.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.82 | Chg30d=+0.062 | Revisions Net=+4 | Analysts=5
EPS current Year (2026-12-31): EPS=7.52 | Chg30d=+0.268 | Revisions Net=+4 | Growth EPS=+14.4% | Growth Revenue=+14.8%
EPS next Year (2027-12-31): EPS=8.24 | Chg30d=+0.228 | Revisions Net=+5 | Growth EPS=+9.6% | Growth Revenue=+9.5%
[Gordon] Analyst Rev G=19.0% | Discount Rate=7.9% | Earnings Yield=2.8% | Net Margin=6.8% | ROE=16.6% | Plowback=114.7% | Payout=-14.7%
[Gordon] Breakeven Revenue = 114.10b USD (current 5.06b)
[Gordon] Implied Growth Rate = 5.2% (Discount Rate 7.9% - Earnings Yield 2.8%)
[Gordon] Growth Spread = +13.8% (Analyst 19.0% - Implied 5.2%)
P/E Forward = 23.5849
P/S = 2.4202
P/B = 5.3326
P/EG = 1.5727
Revenue TTM = 5.06b USD
EBIT TTM = 463.6m USD
EBITDA TTM = 567.9m USD
Long Term Debt = 137.5m USD (from longTermDebt, last quarter)
Short Term Debt = 119.0m USD (from shortTermDebt, last quarter)
Debt = 4.15b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.65b USD (from netDebt column, last quarter)
Enterprise Value = 15.82b USD (12.24b + Debt 4.15b - CCE 572.4m)
Interest Coverage Ratio = 58.04 (Ebit TTM 463.6m / Interest Expense TTM 7.99m)
EV/FCF = 42.68x (Enterprise Value 15.82b / FCF TTM 370.7m)
FCF Yield = 2.34% (FCF TTM 370.7m / Enterprise Value 15.82b)
FCF Margin = 7.33% (FCF TTM 370.7m / Revenue TTM 5.06b)
Net Margin = 6.80% (Net Income TTM 344.0m / Revenue TTM 5.06b)
Gross Margin = 13.74% ((Revenue TTM 5.06b - Cost of Revenue TTM 4.36b) / Revenue TTM)
Gross Margin QoQ = 8.67% (prev 14.67%)
Tobins Q-Ratio = 2.90 (Enterprise Value 15.82b / Total Assets 5.46b)
Interest Expense / Debt = 0.05% (Interest Expense 1.96m / Debt 4.15b)
Taxrate = 26.56% (34.5m / 130.1m)
NOPAT = 340.5m (EBIT 463.6m * (1 - 26.56%))
Current Ratio = 1.42 (Total Current Assets 1.27b / Total Current Liabilities 894.3m)
Debt / Equity = 1.86 (Debt 4.15b / totalStockholderEquity, last quarter 2.23b)
Debt / EBITDA = 6.43 (Net Debt 3.65b / EBITDA 567.9m)
Debt / FCF = 9.85 (Net Debt 3.65b / FCF TTM 370.7m)
Total Stockholder Equity = 2.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.79% (Net Income 344.0m / Total Assets 5.46b)
RoE = 16.58% (Net Income TTM 344.0m / Total Stockholder Equity 2.07b)
RoCE = 20.96% (EBIT 463.6m / Capital Employed (Equity 2.07b + L.T.Debt 137.5m))
RoIC = 15.36% (NOPAT 340.5m / Invested Capital 2.22b)
WACC = 5.07% (E(12.24b)/V(16.40b) * Re(6.78%) + D(4.15b)/V(16.40b) * Rd(0.05%) * (1-Tc(0.27)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.50%
[DCF] Terminal Value 86.66% ; FCFF base≈298.0m ; Y1≈308.0m ; Y5≈348.3m
[DCF] Fair Price = 115.3 (EV 10.35b - Net Debt 3.65b = Equity 6.70b / Shares 58.1m; r=5.90% [WACC]; 5y FCF grow 3.44% → 2.90% )
EPS Correlation: 98.15 | EPS CAGR: 17.63% | SUE: 1.39 | # QB: 1
Revenue Correlation: 99.49 | Revenue CAGR: 18.79% | SUE: -1.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.82 | Chg30d=+0.062 | Revisions Net=+4 | Analysts=5
EPS current Year (2026-12-31): EPS=7.52 | Chg30d=+0.268 | Revisions Net=+4 | Growth EPS=+14.4% | Growth Revenue=+14.8%
EPS next Year (2027-12-31): EPS=8.24 | Chg30d=+0.228 | Revisions Net=+5 | Growth EPS=+9.6% | Growth Revenue=+9.5%
[Gordon] Analyst Rev G=19.0% | Discount Rate=7.9% | Earnings Yield=2.8% | Net Margin=6.8% | ROE=16.6% | Plowback=114.7% | Payout=-14.7%
[Gordon] Breakeven Revenue = 114.10b USD (current 5.06b)
[Gordon] Implied Growth Rate = 5.2% (Discount Rate 7.9% - Earnings Yield 2.8%)
[Gordon] Growth Spread = +13.8% (Analyst 19.0% - Implied 5.2%)